South Texas Alzheimer’s Disease Center Biomarker Core

生物标志物可以加深对生物学的理解，改进风险预测、诊断和预测 阿尔茨海默病及相关疾病(ADRD)的临床前和临床阶段。《公约》的总体目标 生物标记物核心有两个方面：(1)为STAC提供生前生物库服务，即 收集和存储所有登记在临床核心中心的人员(患者、护理伙伴和 在初次和每年的后续访问中估计为265/年，并同样收集和存储 未在CC登记但由另一STAC核心(例如人口核心研究)转介的人的生物谱系 参与者、临床试验患者、脑库捐赠者)以及使用数据、统计管理和 管理核心对这些样本进行编目、跟踪和共享。(2)确定生物标志物进行检测 临床前ADRD，用于预测进展为MCI和ADRD痴呆的风险，并用于鉴别诊断 识别ADRD、MCI和痴呆症的亚型。BC由公元后领军人物韩先林博士领导 代谢组学/脂肪组学和Mini Jacob，医学博士，博士，研究ADRD的感觉-运动生物标志物。我们有 GRECC和胡椒临床中心主任、资深老年病学家Sara Espinoza医学博士补充道 核心。为了实现这些目标：第一，我们将收集、处理、储存、分享和跟踪生物武器 (血清、血浆、外周血单核细胞、DNA、RNA、脑脊液和唾液或粪便，如有指示)，以及 来自个体的非侵入性感觉运动测量，并与他们的临床、成像、基因组和 神经病理学数据。我们将使用最新的生化和分子方法，并应用最佳实践 程序。其次，我们将通过以下方式验证或识别拉美裔人口中的生物标记物 与CC、PNC、GMC、IC和NPC合作，将标记物与临床诊断相关联，病程 疾病、影像和神经病理学。我们将通过提交样本和 将数据整理到NACC、NCRAD和NIAGADS等存储库。第三，我们将确定新的脑脊液和 疑似非阿尔茨海默病(SNAP)患者的血浆代谢生物标志物 合并或不合并2型糖尿病(T2 DM)。通过与CC、PNC和IC合作，我们将确定 伴和不伴T2 DM的SNAP患者(总计300-400人，其中一半为T2 DM，每年约80%)，确定血浆 区分经典生物标志物定义的AD(A/T/N)和SNAP的人体代谢生物标志物 合并和不合并T2 DM。我们希望在SNAP中找到一个独特的生物标记物和代谢特征 AD和合并T2 DM的SNAP有助于我们更好地了解SNAP的生物学，并可能有助于 诊断和治疗。总而言之，卑诗省将收集和分享生物标本，并产生和分享 拉美裔美国人广泛的生物标记物数据，以建立了解异质性的独特资源 ADRD在南得克萨斯州，并用于开发AD个性化治疗。

Biomarkers permit a deeper understanding of biology, improve risk prediction, diagnosis and prognostication at pre-clinical and clinical stages of Alzheimer Disease and Related Disorders (ADRD). The overall goals of the Biomarker core (BC) are two-fold: (1) To provide ante-mortem biobanking services for STAC, that is to collect and store biospecimens for all persons enrolled in the Clinical Core (patients, care partners and controls), an estimated 265/year at their initial and annual follow-up visits, and similarly collect and store biospecimens for persons not enrolled in the CC but referred by another STAC core (e.g. population core study enrollees, clinical trial patients, brain bank donors) and working with the Data, Statistical Management and Administrative Cores catalog, track and share these samples. (2) To identify biomarkers for detecting preclinical ADRD, for risk prediction of progression to MCI and ADRD dementia, and for differential diagnosis and identifying subtypes of ADRD MCI and dementia. The BC is led by Xianlin Han, PhD, a leader in AD metabolomics/lipomics and Mini Jacob, MD, PhD, studying sensory-motor biomarkers in ADRD. We have added Co-I Sara Espinoza, MD, a senior geriatrician who is Director of the GRECC and Pepper Center Clinical Core. To achieve these goals: Firstly, we will collect, process, store, share and track biospecimens (serum, plasma, peripheral blood monocytes, DNA, RNA, CSF and saliva or stool when indicated), as well as non-invasive sensorimotor measures from individuals and link to their clinical, imaging, genomic and neuropathologic data. We will use the latest biochemical and molecular methods and apply best practice procedures. Secondly, we will validate or identify biomarkers among the Hispanic population by collaborating with the CC, PNC, GMC, IC and NPC to correlate the markers with clinical diagnoses, course of disease, imaging and neuropathology. We will make these data publicly available by submitting samples and curated data to repositories such as NACC, NCRAD and NIAGADS. Thirdly, we will identify novel CSF and plasma metabolic biomarkers in individuals with Suspected Non-Alzheimer Pathophysiology (SNAP) with or without type 2 diabetes mellitus (T2DM). In collaboration with the CC, PNC and IC we will identify individuals with SNAP with and without T2DM (300-400 in total, half T2DM at rate of ~80/year), identify plasma metabolic biomarkers distinguishing between classical biomarker-defined AD (A+/T+/N+) and SNAP in persons with and without T2DM. We expect to find a unique biomarker and metabolic signature in SNAP compared to AD and in SNAP with T2DM that will help us better understand the biology of SNAP and may help with diagnosis and treatment. In summary, BC will collect and share biospecimens, and generate and share extensive biomarker data in Hispanics to establish a unique resource for understanding the heterogeneity of ADRD in South Texas and for development of AD personalized treatments.